By contrast, in the United States, most insurance companies only approve GLP-1s for one year, despite its status as a long-term medication. The criteria for coverage in the United States vary greatly depending on BMI and comorbidities
Since it works on both GLP-1 and GIP receptors, it offers dual action, reducing appetite, slowing digestion, and improving insulin sensitivity
Most people are familiar with the severe withdrawal symptoms caused by opioid painkillers
Our clinical observation of a reduced risk for TED-related interventions suggests that the therapeutic application of GLP-1RAs may influence the inflammatory sequelae of thyroid autoimmunity differently than genetic predisposition alone, the researchers wrote
But success is not guaranteed, and expectations should be tempered